enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
前日終値
$8.75
+$0.57 · +6.97%
日中の時刻はETです。市場データは遅延する場合があります。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日中レンジ
現在 $8.75
52週レンジ
現在 $8.75
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
31
割高
センチメント
47
まちまち
リスク
72
高リスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日中レンジ
現在 $8.75
52週レンジ
現在 $8.75
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 52.8万 USD | 54.6万 USD | 52.5万 USD | 45.29万 USD |
| 粗利益 | — | −52.8万 USD | −54.6万 USD | −52.5万 USD | −45.29万 USD |
| 研究開発 | 998.1万 USD | 1224.9万 USD | 1358.3万 USD | 991.4万 USD | 572.76万 USD |
| 販売・一般管理 | 1091.8万 USD | 1104.9万 USD | 1110.9万 USD | 1449.3万 USD | 1071.19万 USD |
| 営業費用 | 2089.9万 USD | 2329.8万 USD | 2469.2万 USD | 2440.7万 USD | 1643.96万 USD |
| 受取利息 | 69.2万 USD | 38.9万 USD | 18万 USD | 16.1万 USD | 1.87万 USD |
| 減価償却費と償却費 | 48.9万 USD | 52.8万 USD | 54.6万 USD | 52.5万 USD | 45.3万 USD |
| 営業利益 | −2089.9万 USD | −2382.6万 USD | −2523.8万 USD | −2493.2万 USD | −1689.25万 USD |
| 純利益 | −1947.2万 USD | −2181.9万 USD | −2351.6万 USD | −2466.9万 USD | −1652.78万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年1月20日 | 1:35 | — | — |
株式分割 | 2020年11月30日 | 1:25 | — | — |
発効済み 2026年1月20日
1:35
発効済み 2020年11月30日
1:25
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。